Comment from Association for Accessible Medicines (AAM)
AnonymousSupportAdvocacy
Summary: The Association for Accessible Medicines (AAM) supports the Commissioner’s National Priority Voucher (CNPV) Pilot Program but argues that it should be expanded to include generic drugs and biosimilars. They advocate for formalizing the program's eligibility criteria and procedures through regulations and guidance to ensure transparency and accountability.
FDA, Please find attached comments from the Association for Accessible Medicines (AAM) regarding Docket No. FDA-2026-N-2366 "Commissioner’s National Priority Voucher (CNPV) Pilot Program; Public Hearing; Request for Comments" Thanks, Scott Kuzner, Ph.D., Senior Director, Sciences and Regulatory Affairs, AAM